



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

16th August 2021
IOLCP/CGC/2021

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

Security Symbol: IOLCP

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400 001

Security Code: 524164

Subject: Submission of newspaper publication of audited financial results for the quarter ended 30th June 2021

Dear Sir,

Pursuant to the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith copies of the newspaper publication of audited financial results for the quarter ended 30th June 2021 published in Business Standard, Economic Times, Financial Express, and Punjabi Jagran on 14th August 2021.

This is for your information and records.

Thanking You,

Yours faithfully,
For IOL Chemicals and Pharmaceuticals Limited

Abhay Raj Singh
VP & Company Secretary





	Year ended 31.03.2021
6	3,60,572.31
8	29,190.88
8	30,109.65
5	21,343.45
9	23,208.17
5	6,290.14
	2,14,690.85
9	12.92
9	12.92

013, read with

Regulation 33
ed 30.06.2021
ia.com.

er of the Board
शुभश कुमार

(Subhash Kumar)
Managing Director

Limited

retariat@ngc.co.in

Official



IOL Chemicals and Pharmaceuticals Limited

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021

(in ₹ Crore)

Sr. No.	Particulars	Quarter ended			Year ended
		30.06.2021 (Audited)	31.03.2021 (Audited)	30.06.2020 (Audited)	31.03.2021 (Audited)
1	Total Income from operations	524.23	466.59	465.91	1,991.28
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	103.78	105.97	146.74	571.39
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	89.85	105.97	146.74	571.39
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	67.00	75.25	127.54	444.56
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	66.52	75.55	126.96	442.42
6	Equity share capital	58.71	58.71	58.71	58.71
7	Other equity (Reserves excluding revaluation reserve)				1,201.72
8	Earning per share (of ₹10/- each) (for continuing and discontinued operations) (not annualised except for year ended 31.03.2021)				
	Basic & Diluted ₹	11.41	12.76	22.30	76.21

NOTES:

- The above is an extract of the detailed format of audited financial results for the quarter ended 30-June-2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these financial results is available on the Stock Exchange websites i.e. www.bseindia.com & www.nseindia.com and Company's website www.iolcp.com.
- The above results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors in their respective meetings held on 13th August, 2021.
- The Company has successfully setup a new manufacturing facility ('Unit-10') for manufacturing multiple Pharma (API's) products with a capex of ₹ 28.69 Crore. The installation of new manufacturing facility ('Unit - 9') for Gabapentin & Other Pharma (API's) Products is slightly delayed of its schedule due to 2nd wave of COVID-19 and expected to complete in 3rd quarter of FY 2022 without any cost overrun. The capital expenditure for installation of both the new manufacturing facilities has been/ is being met through internal accruals only.
- The exceptional items amounting to ₹ 13.93 crores represent one time cost towards Right of Recompense (RoR) payable to the lenders against sacrifices made by them in FY 2014-15 on account of restructuring done under Joint Lenders Forum (JLF) route.
- The previous financial period figures have been regrouped/rearranged/restated wherever considered necessary.

By order of the Board
For IOL Chemicals and Pharmaceuticals Limited
Sd/-
Varinder Gupta
Managing Director
DIN-00044068

Place: Ludhiana
Date: 13th August 2021

CIN: L24116PB1986PLC007030.

Regd Office: Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab
Ph. +91-1679-285285-86, Fax: +91-1679-285292, E-mail: contact@iolcp.com, www.iolcp.com

Place : Ludhiana

Date : 03-08-2021

VANDANA KANSAL

Place : Ludhiana

Date : 03-08-2021

PADAM PARKASH KANSAL



IOL Chemicals and Pharmaceuticals Limited

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021

(in ₹ Crore)

Sr. No.	Particulars	Quarter ended			Year ended
		30.06.2021	31.03.2021	30.06.2020	31.03.2021
		(Audited)	(Audited)	(Audited)	(Audited)
1	Total Income from operations	524.23	466.59	465.91	1,991.28
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	103.78	105.97	146.74	571.39
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	89.85	105.97	146.74	571.39
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	67.00	75.25	127.54	444.56
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	66.52	75.55	126.96	442.42
6	Equity share capital	58.71	58.71	58.71	58.71
7	Other equity (Reserves excluding revaluation reserve)				1,201.72
8	Earning per share (of ₹10/- each) (for continuing and discontinued operations) (not annualised except for year ended 31.03.2021)				
	Basic & Diluted ₹	11.41	12.76	22.30	76.21

NOTES:

- The above is an extract of the detailed format of audited financial results for the quarter ended 30-June-2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these financial results is available on the Stock Exchange websites i.e. www.bseindia.com & www.nseindia.com and Company's website www.iolcp.com.
- The above results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors in their respective meetings held on 13th August, 2021.
- The Company has successfully setup a new manufacturing facility ('Unit-10') for manufacturing multiple Pharma (API's) products with a capex of ₹ 28.69 Crore. The installation of new manufacturing facility ('Unit - 9') for Gabapentin & Other Pharma (API's) Products is slightly delayed of its schedule due to 2nd wave of COVID-19 and expected to complete in 3rd quarter of FY 2022 without any cost overrun. The capital expenditure for installation of both the new manufacturing facilities has been/is being met through internal accruals only.
- The exceptional items amounting to ₹ 13.93 crores represent one time cost towards Right of Recompense (RoR) payable to the lenders against sacrifices made by them in FY 2014-15 on account of restructuring done under Joint Lenders Forum (JLF) route.
- The previous financial period figures have been regrouped/rearranged/restated wherever considered necessary.

By order of the Board
For IOL Chemicals and Pharmaceuticals Limited
Sd/-
Varinder Gupta
Managing Director
DIN-00044068

Place: Ludhiana
Date: 13th August 2021

CIN: L24116PB1986PLC007030,

Regd Office: Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab
Ph. +91-1679-285285-86, Fax: +91-1679-285292, E-mail: contact@iolcp.com, www.iolcp.com

re
subsidia-
eased by a
r the repor-
66 crore in
The airline
cargo sube-
e impact of
e and more

e been the
SpiceJet as
it sector du-
l was seve-
rave as pas-
sured. While
with vacci-
nd demand
dily, we ho-

LUXURY TAX ELHI 10002

Date: 13.08.2021
one wise electronic
ind Foreign Liquor
EMD details and

or (Except Country

pplicant is going to

d for one zone
l for more than one

cence in one zone,
e Tender Reference
28.06.2021, shall
e number of zones

ough Google Meet

onwards
rs)

) hours) in the drop
ment of Excise,
f NCT of Delhi, L &
-110002

i Conference room,
ent and Luxury Tax,
Vikas Bhawan, IP

ry Tax, L&N Block,

ould be submitted
) have appropriate
ce provider of NIC.
ed) on any working
ng, Vikas Bhawan-
00 P.M.) Tel: 011-

ihl.gov.in and on
seen in the notice

Sd/-
iopi Krishna)
ioner (Excise)

TAX BREAKS

Threshold return-on-equity of

Tamil Nadu cuts tax budget

leasing model with an aim to will not be less than 14%.

Date: 12.08.2021



IOL Chemicals and Pharmaceuticals Limited

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021

(In ₹ Crore)

Sr. No.	Particulars	Quarter ended			Year ended
		30.06.2021 (Audited)	31.03.2021 (Audited)	30.06.2020 (Audited)	31.03.2021 (Audited)
1	Total Income from operations	524.23	466.59	465.91	1,991.28
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	103.78	105.97	146.74	571.39
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	89.85	105.97	146.74	571.39
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	67.00	75.25	127.54	444.56
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	66.52	75.55	126.96	442.42
6	Equity share capital	58.71	58.71	58.71	58.71
7	Other equity (Reserves excluding revaluation reserve)				1,201.72
8	Earning per share (of ₹10/- each) (for continuing and discontinued operations) (not annualised except for year ended 31.03.2021)				
	Basic & Diluted ₹	11.41	12.76	22.30	76.21

NOTES:

- The above is an extract of the detailed format of audited financial results for the quarter ended 30-June-2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these financial results is available on the Stock Exchange websites i.e. www.bseindia.com & www.nseindia.com and Company's website www.iolcp.com.
- The above results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors in their respective meetings held on 13th August, 2021.
- The Company has successfully setup a new manufacturing facility ('Unit-10') for manufacturing multiple Pharma (API's) products with a capex of ₹ 28.69 Crore. The installation of new manufacturing facility ('Unit - 9') for Gabapentin & Other Pharma (API's) Products is slightly delayed of its schedule due to 2nd wave of COVID-19 and expected to complete in 3rd quarter of FY 2022 without any cost overrun. The capital expenditure for installation of both the new manufacturing facilities has been/ is being met through internal accruals only.
- The exceptional items amounting to ₹ 13.93 crores represent one time cost towards Right of Recompense (RoR) payable to the lenders against sacrifices made by them in FY 2014-15 on account of restructuring done under Joint Lenders Forum (JLF) route.
- The previous financial period figures have been regrouped/rearranged/restated wherever considered necessary.

By order of the Board
For IOL Chemicals and Pharmaceuticals Limited
Sd/-
Varinder Gupta
Managing Director
DIN-00044068

Place: Ludhiana
Date: 13th August 2021

CIN: L24116PB1986PLC007030

Regd Office: Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab
Ph. +91-1679-285285-86. Fax: +91-1679-285292. E-mail: contact@iolcp.com, www.iolcp.com



BEGIN
HEALTH
TODAY

#JumKe

ER ENDED 30 JUNE 2021

Quarter ended	
30-06-2021 (Unaudited)	30-06 (Unau)
103088	
18607	
14076	
14019	
2354	
-	
5.98	
5.98	

33
ReveConsiste
on gr12%
PBT YOY

ce: 5190, Lahori Gate, D
IPLC052845, Email: inve
com, Tel.: +91-11-239683

ਕਮ-
ਜ਼ਾਲਾ।

ਤੇ ਉਨ੍ਹਾਂ ਦੀ
ਕ ਥਾਵਾਂ 'ਤੇ
ਕ ਇਸ ਨਾਲ
ਮਦਾ ਕਰਨਾ
ਜਾਵੇ।

ਖਿਆ ਜਾਵੇ।
ਰ ਨਾ ਸੁੱਟੋ।

ਬਰਨਾਲਾ ਨੂੰ

ਧਕ ਅਫ਼ਸਰ
ਵਿੰਦਰ ਸਿੰਘ
ਜੀ, ਬਰਨਾਲਾ।



ਆਈਓਐਲ ਕੈਮੀਕਲਜ਼ ਐਂਡ ਫਾਰਮਾਸਿਊਟੀਕਲਜ਼ ਲਿਮਿਟਿਡ

ਮਿਤੀ 30 ਜੂਨ, 2021 ਨੂੰ ਖਤਮ ਹੋਈ ਤਿਮਾਹੀ ਵਾਸਤੇ ਆਡਿਟਿਡ ਵਿੱਤੀ ਨਤੀਜਿਆਂ ਦਾ ਸਾਰ

(ਰੁ. ਕਰੋੜ 'ਚ)

ਲੜੀ ਨੰ.	ਵੇਰਵੇ	ਖਤਮ ਹੋਈ ਤਿਮਾਹੀ			ਖਤਮ ਹੋਈਆਂ ਸਾਲ
		30.06.2021 (ਆਡਿਟਿਡ)	31.03.2021 (ਆਡਿਟਿਡ)	30.06.2020 (ਆਡਿਟਿਡ)	31.03.2021 (ਆਡਿਟਿਡ)
1	ਆਪਰੇਸ਼ਨਜ਼ ਤੋਂ ਕੁੱਲ ਆਮਦਨ	524.23	466.59	465.91	1,991.28
2	ਅਰਜੇ ਲਈ ਸ਼ੁੱਧ ਲਾਭ (ਟੈਕਸ ਤੋਂ ਪਹਿਲਾਂ, ਐਕਸੈਪਸ਼ਨਲ ਅਤੇ/ਜਾਂ ਵਿਸ਼ੇਸ਼ ਆਈਟਮਾਂ)	103.78	105.97	146.74	571.39
3	ਟੈਕਸ ਤੋਂ ਪਹਿਲਾਂ ਅਰਜੇ ਵਾਸਤੇ ਸ਼ੁੱਧ ਲਾਭ (ਐਕਸੈਪਸ਼ਨਲ ਅਤੇ/ਜਾਂ ਵਿਸ਼ੇਸ਼ ਆਈਟਮਾਂ ਤੋਂ ਬਾਅਦ)	89.85	105.97	146.74	571.39
4	ਟੈਕਸ ਪਿੱਛੋਂ ਅਰਜੇ ਵਾਸਤੇ ਸ਼ੁੱਧ ਲਾਭ (ਐਕਸੈਪਸ਼ਨਲ ਅਤੇ/ਜਾਂ ਵਿਸ਼ੇਸ਼ ਆਈਟਮਾਂ ਤੋਂ ਬਾਅਦ)	67.00	75.25	127.54	444.56
5	ਅਰਜੇ ਵਾਸਤੇ ਕੁੱਲ ਸੰਖੇਪ ਆਮਦਨ (ਲਾਭ/(ਹਾਨੀ) ਸ਼ਾਮਲ) ਅਰਜੇ ਵਾਸਤੇ (ਟੈਕਸ ਪਿੱਛੋਂ) ਅਤੇ ਹੋਰ ਸੰਖੇਪ ਆਮਦਨ (ਟੈਕਸ ਪਿੱਛੋਂ)	66.52	75.55	126.96	442.42
6	ਇਕੁਇਟੀ ਸ਼ੇਅਰ ਕੈਪੀਟਲ	58.71	58.71	58.71	58.71
7	ਹੋਰ ਇਕੁਇਟੀ (ਰਾਖਵਿਆਂ ਨੂੰ ਛੱਡ ਕੇ ਮੁੜ ਮੁਲਾਂਕਣ ਰਾਖਵਾਂ)				1,201.72
8	ਪ੍ਰਤੀ ਸ਼ੇਅਰ ਆਮਦਨ (ਰੁ. 10/- ਹਰੇਕ ਦਾ) (ਚਲਦੇ ਅਤੇ ਨਾ ਚਲਦੇ ਆਪਰੇਸ਼ਨਜ਼ ਵਾਸਤੇ) (ਮਿਤੀ 31.03.2021 ਨੂੰ ਖਤਮ ਹੋਏ ਸਾਲ ਲਈ ਸਿਵਾਏ ਸਾਲਾਨਾ ਨਹੀਂ) ਬੈਨਿਕ ਅਤੇ ਡਿਊਟਿਡ ਟੋ	11.41	12.76	22.30	76.21

ਟਿੱਪਣੀਆਂ :

- ਉਪਰੋਕਤ ਐਸਈਓਐਲ (ਲਿਸਟਿੰਗ ਅਤੇ ਡਿਸਕਲੋਜ਼ਰ ਜਰੂਰਤਾਂ) ਰੈਗੂਲੇਸ਼ਨਜ਼ 2015 ਦੇ ਰੈਗੂਲੇਸ਼ਨਜ਼ 33 ਅਧੀਨ ਸਟਾਕ ਐਕਸਚੇਂਜਾਂ ਕੋਲ 30 ਜੂਨ, 2021 ਨੂੰ ਖਤਮ ਹੋਈ ਤਿਮਾਹੀ ਦੇ ਵਿੱਤੀ ਨਤੀਜਿਆਂ ਦੇ ਵਿਸਥਾਰਿਤ ਫਾਰਮੈਟ ਦਾ ਇੱਕਸਾਰ ਹੈ। ਇਨ੍ਹਾਂ ਵਿੱਤੀ ਨਤੀਜਿਆਂ ਦਾ ਪੂਰਾ ਫਾਰਮੈਟ ਸਟਾਕ ਐਕਸਚੇਂਜ ਦੀਆਂ ਵੈੱਬਸਾਈਟਾਂ ਅਰਥਾਤ www.bseindia.com ਅਤੇ www.nseindia.com ਅਤੇ ਕੰਪਨੀ ਦੀ ਵੈੱਬਸਾਈਟ www.iolcp.com ਉੱਪਰ ਉਪਲਬਧ ਹੈ।
- ਉਕਤ ਨਤੀਜਿਆਂ ਦਾ ਆਡਿਟ ਕਮੇਟੀ ਦੁਆਰਾ ਰੀਵਿਊ ਕੀਤਾ ਜਾ ਚੁੱਕਾ ਹੈ ਅਤੇ ਇਸ ਤੋਂ ਬਾਅਦ ਮਿਤੀ 13 ਅਗਸਤ, 2021 ਨੂੰ ਹੋਈਆਂ ਸਬੰਧਿਤ ਉਨ੍ਹਾਂ ਦੇ ਨਿਰਦੇਸ਼ਕਾਂ ਦੇ ਬੋਰਡ ਦੁਆਰਾ ਮੀਟਿੰਗ ਵਿੱਚ ਪ੍ਰਵਾਨ ਕੀਤੇ ਗਏ ਹਨ।
- ਕੰਪਨੀ ਨੇ ਰੁ. 28.69 ਕਰੋੜ ਦੇ ਇੱਕ ਕੰਪੋਜ਼ ਮੈਨੂਫੈਕਚਰਿੰਗ ਮਲਟੀਪਲ ਫ਼ਾਰਮਾ (ਏਪੀਆਈਐੱਫ) ਪ੍ਰੋਡਕਟਸ ਵਾਸਤੇ ਇੱਕ ਨਵੀਂ ਉਤਪਾਦਨ ਸਹੂਲਤ ("ਯੂਨਿਟ-10") ਸਫਲਤਾਪੂਰਵਕ ਸਥਾਪਿਤ ਕੀਤੀ ਹੈ। ਗਾਥਾ ਪੈਨਟਿਨ ਅਤੇ ਹੋਰ ਫ਼ਾਰਮਾ (ਏਪੀਆਈਐੱਫ) ਪ੍ਰੋਡਕਟਸ ਨਵੀਂ ਉਤਪਾਦਨ ਸਹੂਲਤ ("ਯੂਨਿਟ-09") ਦੀ ਸਥਾਪਨਾ ਵਿੱਚ ਕੋਵਿਡ-19 ਦੀ ਦੂਸਰੀ ਲਹਿਰ ਅਤੇ ਵਿੱਤੀ ਸਾਲ 2022 ਦੀ ਤੀਜੀ ਤਿਮਾਹੀ ਦੇ ਪੂਰਾ ਹੋਣ ਤੋਂ ਇਲਾਵਾ ਕੁਝ ਦੇਰ ਹੋਈ ਹੈ, ਬਿਨਾਂ ਕਿਸੇ ਚਿੰਤਨ ਦੇ/ਦੇਵੇਂ ਨਵੀਆਂ ਉਤਪਾਦਨ ਸਹੂਲਤਾਂ ਦੀ ਸਥਾਪਨਾ ਵਾਸਤੇ ਮੁੱਢਲੇ ਖਰਚੇ ਕੇਵਲ ਅੰਦਰੂਨੀ ਇਕੱਤਰਤਾ ਰਾਹੀਂ ਪੂਰੀ ਕੀਤੇ ਗਏ ਹਨ/ਪੂਰੇ ਕੀਤੇ ਜਾਣੇ ਹਨ।
- ਰੁ. 13.93 ਕਰੋੜ ਵਿਸ਼ੇਸ਼ ਆਈਟਮਾਂ ਦੀ ਇਕ ਸਮੇਂ ਵਾਸਤੇ ਰੀਕੰਪੈਨਸ (ਆਰਓਆਰ) ਪ੍ਰਤੀ ਜੁਆਇੰਟ ਲੈਂਡਰਜ਼ ਫੋਰਮ (ਜੇਐੱਲਐੱਫ) ਰੁਟ ਅਧੀਨ ਨਵੀਨੀਕਰਨ ਲਈ ਵਿੱਤੀ ਸਾਲ 2014-15 ਵਿੱਚ ਉਨ੍ਹਾਂ ਦੁਆਰਾ ਕੀਤੇ ਤਿਆਗਾਂ ਲਈ ਖਰਚੇ ਗਏ ਹਨ।
- ਪਿਛਲੇ ਵਿੱਤੀ ਅਰਜੇ ਵਾਸਤੇ ਐਕਸ਼ੀਅਨ ਨੂੰ ਰੀਗਰੂਪਿੰਗ/ਰੀਅਰੇਂਜਡ/ਰੀਸਟ੍ਰਕਚਰ ਕੀਤਾ ਗਿਆ ਹੈ, ਜਿੱਥੇ ਲਾਜ਼ਮੀ ਸਮਝਿਆ ਗਿਆ ਹੈ।

ਬਾ-ਹੁਕਮ ਬੋਰਡ
ਵਾਸਤੇ ਆਈਓਐਲ ਕੈਮੀਕਲਜ਼ ਐਂਡ ਫਾਰਮਾਸਿਊਟੀਕਲਜ਼ ਲਿਮਿਟਿਡ
ਸਹੀ/-
ਵਿੰਦਰ ਗੁਪਤਾ
ਮੈਨੇਜਿੰਗ ਡਾਇਰੈਕਟਰ
ਡੀਆਈਐੱਨ-00044068

ਸਥਾਨ : ਲੁਧਿਆਣਾ
ਮਿਤੀ : 13 ਅਗਸਤ, 2021

CIN: L24116PB1986PLC007030.
ਰਜਿ. ਆਫਿਸ : ਪਿੰਡ ਤੇ ਡਾਕਖਾਨਾ ਹੌਡਿਆਇਆ, ਫਤਹਿਗੜ੍ਹ ਚਾਨਾ ਰੋਡ, ਬਰਨਾਲਾ-148107, ਪੰਜਾਬ
ਫੋਨ: +91-1679-285285-86, ਫੈਕਸ: +91-1679-285292, ਈ-ਮੇਲ: contact@iolcp.com, www.iolcp.com